Brief: Vistagen Announces Positive Results From Exploratory Phase 2A Study Of Ph80 In Women Diagnosed With Menopausal Hot Flashes

Vistagen Therapeutics

07/06/2023 14:38

VistaGen Therapeutics Inc  VTGN.O :
    * VISTAGEN ANNOUNCES POSITIVE RESULTS FROM EXPLORATORY PHASE
2A
STUDY OF PH80 IN WOMEN DIAGNOSED WITH MENOPAUSAL HOT FLASHES
    * VISTAGEN THERAPEUTICS INC - PH80 WAS SAFE AND
WELL-TOLERATED
WITH AN ADVERSE EVENT PROFILE SIMILAR TO PLACEBO
    * VISTAGEN THERAPEUTICS - ALL 36 SUBJECTS COMPLETED 4 WEEKS
OF
TREATMENT & NO SUBJECT DISCONTINUED PARTICIPATION IN STUDY AS A
RESULT OF ADVERSE EVENTS
    * VISTAGEN THERAPEUTICS INC - PH80 INDUCED SIGNIFICANT
REDUCTION
IN DAILY NUMBER OF HOT FLASHES COMPARED TO PLACEBO AT END OF
FIRST WEEK OF TREATMENT

Source text for Eikon:  ID:nBw1pNGKra 
Further company coverage:  VTGN.O